A new collaboration aims to accelerate development of advanced G-protein coupled receptor (GPCR)-targeting therapeutics for cachexia caused by cancer and other chronic conditions.  Orbit Discovery has entered a partnership with Endevica Bio following the release of data proving that the company’s lead compound is safe and well-tolerated in Phase I trials.  Endevica’s technology platform allows […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!